Lexeo Therapeutics announced that the company will conduct an investor webcast on Monday, July 15, 2024, at 8:00 AM ET to provide an interim clinical data update on LX2006, an AAVrh10.hFXN gene therapy for the treatment of Friedreich ataxia cardiomyopathy. The presentation will include an overview of the natural history of FA cardiomyopathy and summary of clinically meaningful endpoints, interim data from Lexeo’s ongoing SUNRISE-FA Phase 1/2 clinical trial and the ongoing Weill Cornell Medicine investigator-initiated trial, as well as an overview of program next steps.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LXEO:
- Lexeo Therapeutics Welcomes New Board Member Tim Van Hauwermeiren
- Lexeo Therapeutics appoints Tim Van Hauwermeiren to board of directors
- Lexeo Therapeutics Appoints Tim Van Hauwermeiren to its Board of Directors
- Lexeo Therapeutics initiated with an Outperform at Baird
- Lexeo Therapeutics initiated with a Buy at H.C. Wainwright